JP2024539952A - 放射性核種錯体の組み合わせ療法 - Google Patents

放射性核種錯体の組み合わせ療法 Download PDF

Info

Publication number
JP2024539952A
JP2024539952A JP2024524610A JP2024524610A JP2024539952A JP 2024539952 A JP2024539952 A JP 2024539952A JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024539952 A JP2024539952 A JP 2024539952A
Authority
JP
Japan
Prior art keywords
dota
weeks
subject
mci
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539952A5 (enExample
Inventor
ダニエラ アイモネ，パオラ
チッコ，ダニエラ
エフ． マリアニ，マウリツィオ
ゾール，エヴレン
Original Assignee
ノバルティス アーゲー
アドバンスド アクセラレーター アプリケーションズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, アドバンスド アクセラレーター アプリケーションズ filed Critical ノバルティス アーゲー
Publication of JP2024539952A publication Critical patent/JP2024539952A/ja
Publication of JP2024539952A5 publication Critical patent/JP2024539952A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024524610A 2021-10-27 2022-10-27 放射性核種錯体の組み合わせ療法 Pending JP2024539952A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (2)

Publication Number Publication Date
JP2024539952A true JP2024539952A (ja) 2024-10-31
JP2024539952A5 JP2024539952A5 (enExample) 2025-11-04

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524610A Pending JP2024539952A (ja) 2021-10-27 2022-10-27 放射性核種錯体の組み合わせ療法

Country Status (11)

Country Link
US (1) US20250387523A1 (enExample)
EP (1) EP4422701A1 (enExample)
JP (1) JP2024539952A (enExample)
KR (1) KR20240093832A (enExample)
CN (1) CN118159304A (enExample)
AU (1) AU2022374887A1 (enExample)
CA (1) CA3234495A1 (enExample)
IL (1) IL312106A (enExample)
MX (1) MX2024004961A (enExample)
TW (1) TW202332473A (enExample)
WO (1) WO2023073603A1 (enExample)

Also Published As

Publication number Publication date
US20250387523A1 (en) 2025-12-25
CA3234495A1 (en) 2023-05-04
CN118159304A (zh) 2024-06-07
WO2023073603A1 (en) 2023-05-04
AU2022374887A1 (en) 2024-04-11
TW202332473A (zh) 2023-08-16
MX2024004961A (es) 2024-05-08
IL312106A (en) 2024-06-01
EP4422701A1 (en) 2024-09-04
KR20240093832A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
US20250195701A1 (en) Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
JP7839135B2 (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
JP2021506784A (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
US20240066156A1 (en) Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination
HU221423B1 (en) Tin-117m-containing radiotherapeutic agents
JP2026505341A (ja) 神経膠芽腫を治療するための方法
AU2022374887A1 (en) Combination therapy of radionuclide complex
US8268888B2 (en) Therapy of malignant neoplasias
EP4735056A1 (en) Methods for the diagnosis and/or treatment of neuroendocrine cancers
WO2025126151A1 (en) Methods for treating breast cancer
KR20250109190A (ko) 암의 식별 및/또는 치료
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251024